‘

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):  August 25, 2016

 

Derma Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware	1-31070	23-2328753
(State or other jurisdiction	(Commission	(IRS employer
of incorporation)	File Number)	identification number)

 

214 Carnegie Center, Suite 300

Princeton, NJ  08540

(609) 514-4744

(Address including zip code and telephone

number, of principal executive offices)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

Item 5.02  Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers.

 

(e)

 

Discretionary Bonus

 

Effective August 25, 2016, the Board of Directors of Derma Sciences, Inc. (the “Company”) granted a one-time cash bonus of $200,000 to Stephen T. Wills, as interim principal executive officer. The grant was made in connection with Mr. Wills’ efforts, additional time commitments and responsibilities over the last eight months, including spearheading the sale of the Company’s First Aid Division, expected to close by the end of August 2016, and the acquisition of BioD, LLC, which included an equity raise of $2.3 million, both of which closed on August 5, 2016. Mr. Wills has served in the capacity of interim principal executive officer since January 1, 2016 at a compensation rate of $15,000 per month.

  

 

  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	DERMA SCIENCES, INC.
	By:	/s/ John E. Yetter
		John E. Yetter, CPA
		Executive Vice President, Finance and Chief Financial Officer

Date:  August 26, 2016